$144 Million

NGM Biopharmaceuticals, Inc.

Follow-on Offering

Bookrunner, January 2021

NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer. The Company’s lead product candidate, aldafermin (formerly known as NGM282), is an engineered version of the human hormone FGF19 that is administered through a once-daily subcutaneous injection.